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Background:Themechanism bywhich TGF-1 down-regulatesmiR-130b to promote diabetic nephropathy (DN) remains
unclear.
Results:TGF-1 initiates a signaling cascade, includingNF-YC, RIK,miR-130b, andTGF-R1, inmesangial cells to up-regulate
profibrotic genes related to DN pathogenesis.
Conclusion: A novel pathway involving microRNAs and the host gene can augment mesangial fibrosis.
Significance: The reno-protective effects of miR-130b could be exploited for DN treatment.
Increased expression of transforming growth factor-1
(TGF-1) in glomerular mesangial cells (MC) augments
extracellular matrix accumulation and hypertrophy during
the progression of diabetic nephropathy (DN), a debilitating
renal complication of diabetes. MicroRNAs (miRNAs) play
key roles in the pathogenesis of DN bymodulating the actions
of TGF-1 to enhance the expression of profibrotic genes like
collagen. In this study, we found a significant decrease in the
expression of miR-130b in mouse MC treated with TGF-1.
In parallel, there was a down-regulation in miR-130b host
gene 2610318N02RIK (RIK), suggesting host gene-dependent
expression of this miRNA. TGF- receptor 1 (TGF-R1) was
identified as a target of miR-130b. Interestingly, the RIK pro-
moter contains three NF-Y binding sites and was regulated by
NF-YC. Furthermore, NF-YC expression was inhibited by
TGF-1, suggesting that a signaling cascade, involving TGF-
1-induced decreases in NF-YC, RIK, andmiR-130b, may up-
regulate TGF-R1 to augment expression of TGF-1 target
fibrotic genes. miR-130b was down-regulated, whereas TGF-
R1, as well as the profibrotic genes collagen type IV  1
(Col4a1), Col12a1, CTGF, and PAI-1 were up-regulated not
only in mouse MC treated with TGF-1 but also in the
glomeruli of streptozotocin-injected diabetic mice, support-
ing in vivo relevance. Together, these results demonstrate a
novel miRNA- and host gene-mediated amplifying cascade
initiated by TGF-1 that results in the up-regulation of pro-
fibrotic factors, such as TGF-R1 and collagens associated
with the progression of DN.
MicroRNAs (miRNAs)2 are endogenously produced single-
stranded, short (average 22 nucleotides), non-coding regula-
tory RNAs that can repress target gene expression (1, 2).
Increasing evidence shows thatmiRNAsplay important roles in
gene regulation by binding to the 3-untranslated regions (3-
UTRs) of their target mRNAs to block protein translation or to
induce mRNA degradation. Thus, miRNAs have the potential
to regulate a multitude of genes under specific physiological
and pathological conditions. miRNAs are emerging as impor-
tant players and modulators in the pathogenesis of many
human diseases, including diabetic nephropathy (DN), a severe
microvascular complication of diabetes.
Key structural features of DN include glomerular mesangial
cell expansion and hypertrophy due to increased accumulation
of extracellular matrix (ECM) proteins, such as collagens and
fibronectin, as well as glomerular basement membrane thick-
ening, tubulointerstitial fibrosis, and podocyte apoptosis, all of
which contribute to renal dysfunction and end stage renal fail-
ure (3–5). Several biochemical pathways and profibrotic fac-
tors, such as transforming growth factor-1 (TGF-1) and
angiotensin II, can enhance the expression of ECM proteins,
including collagen, in renal cells and have been implicated in
the pathogenesis of DN (3, 6–11). Increased TGF-1 expres-
sion in glomerular mesangial cells (MC) has been shown to
promote the accumulation of fibrotic factors, ECM proteins,
and hypertrophy during the progression of DN (4, 5, 7–9, 12).
Studies from our laboratory and others have recently demon-
strated the mediatory role of several miRNAs and their key
target genes in the actions of TGF-1 and high glucose in MC
and other renal cells related to the pathogenesis ofDNaswell as
molecular mechanisms of regulation of key miRNAs by
TGF-1 and high glucose (13–21). However, it is likely that
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there are other as yet unidentifiedmiRNAs thatmodulateTGF-
1-induced regulation of ECM genes in MC to promote DN.
We hypothesized that keymiRNAs that target the same gene
may exert synergistic and amplifying effects in the diabetic kid-
ney. While examining miRNAs that are differentially regulated
by TGF-1 in renalMMC and in glomeruli of diabetic mice, we
observed a significant down-regulation in the miRNAs, miR-
130b and let-7b. Interestingly, through computational target
predictions, we identified TGF- receptor 1 (TGF-R1), which
mediates the fibrotic actions of TGF-1, as a potential target for
both miRNAs, miR-130b and let-7b. let-7b was originally iden-
tified in Caenorhabditis elegans as an important regulator for
normal development (22). The let-7 family is highly conserved
among various species. In mice and humans, it consists of 11
very closely related family members (23). let-7 family members
have been extensively studied for their tumor-suppressive
functions in lung, pancreatic, and breast cancer cells (24, 25).
let-7b inhibits the expression of key oncogenes, such as MYC,
RAS, andHMGA2 (26–28). let-7 is regulated by the RNA-bind-
ing protein, Lin28, which inhibits the processing of let-7 family
miRNAs and their expression levels. Thus, the expression levels
of let-7 and Lin28 are inversely correlated (29). Recently, it was
found that under normal conditions, let-7 maintains low levels
of TGF-R1 expression in human umbilical vein endothelial
cells and in adult human liver cells (30, 31). In addition, in
tubular epithelial cells, lipoxins were shown to down-regulate
TGF-R1-induced fibrosis by up-regulating let-7c (32).
Another recent paper also showed that let-7b targets TGF-R1
related to kidney fibrosis (33). On the other hand, very little is
known about the function ofmiR-130b in any cellular system.A
few reports indicate that miR-130b promotes the growth and
self-renewal of CD133 (hepatocellular carcinoma marker)
liver tumor-initiating cells via down-regulation of TP53INP1
(34, 35). However, the function ofmiR-130b inDN is unknown,
and it is also not known if it cooperates with let-7b. Herein, we
report the identification of miR-130b as a new endogenous
anti-fibrotic protectivemiRNA inMCand also a novelmiRNA-
mediated cascade, whereTGF-1 is able to enhance the expres-
sion of TGF-R1 and collagens via the regulation of a cascade of
key interacting mediators (NF-YC, 2610318N02RIK, miR-
130b, and let-7b) to promote the progression of DN. Together,
these data provide further insights into the complex amplifying
cross-talk between growth factors andmiRNAs and the related
post-transcriptional regulatory mechanisms that modulate the
progression of DN and also identify additional miRNAs that
can be evaluated as therapeutic targets.
EXPERIMENTAL PROCEDURES
Cell Culture—Primary MMC were isolated and cultured in
RPMI 1640 medium supplemented with 10% FBS as described
previously (7). Recombinant human TGF-1 was purchased
from R&D Systems (Minneapolis, MN) and used at a final con-
centration of 10 ng/ml.
Mouse Models—All animal studies were performed in
accordance with a protocol approved by the Institutional Ani-
mal Care and Use Committee. C57BL/6 mice (Jackson Labora-
tories, Bar Harbor, ME) were injected with 50 mg/kg strepto-
zotocin (STZ) intraperitoneally for 5 consecutive days. Blood
glucose levels weremeasured 1week after final STZ injection to
confirm the onset of diabetes (fasting glucose300mg/dl). For
this study, mice were sacrificed 4 weeks after the onset of dia-
betes. Sieved glomeruli from mouse renal cortical tissue were
prepared as described (14, 15) and stored at80 °C for further
analysis.
Real-time Quantitative PCR—RNA was extracted from
MMC using miRNeasy columns (Qiagen, Inc., Valencia, CA).
The qScript miRNA cDNA synthesis kit (Quanta Biosciences,
Gaithersburg, MD) or GeneAmp RNA PCR kit (Applied Bio-
systems, Carlsbad, CA) were utilized for cDNA synthesis. Har-
vested mature miRNAs were polyadenylated in a poly(A)
polymerase reaction. The poly(A) tailed miRNAs were then
converted to cDNAs using an oligo(dT) primer with universal
tag. Forward-specific primer sequences were designed for
amplification of mature miRNAs, and reverse primers were
provided by the cDNA kit. PerfeCTa SYBR Green Supermix
(Quanta Biosciences) or POWER SYBR Green mix (Applied
Biosystems) was used for quantitative PCR amplification on a
7500 real-time PCR system (Applied Biosystems, Foster City,
CA) according to the manufacturer’s protocol. PCR primer
sequences were designed as follows: TGF-R1, 5-CGGTTCT-
ACTTTTCTCATTTCTTCAACCG-3 and 5- AAATTGCT-
CGACGCTGTTCTATTG-3; RIK, 5-AAAGAGCCACATG-
GTTGATCTGA-3 and 5-CGGAGTATGAGAAATGGAA-
GCCTCCG-3; Col4a1, 5-GCCTTCCGGGCTCCTCAG-3
and 5-TTATCACCAGTGGGTCCG-3; Col12a1, 5-TTTG-
CCTGGAGAGAAAGGTG-3 and 5-GATACCTGAGTTT-
CCTGGAC-3; NF-YC, 5-ACAGAGGATAACAAGCG-
TCG-3 and 5-GTCACAGACTGGCGTACC-3; CTGF, 5-
GCGAAGCTGACCTGGAGGA-3 and 5-CGCACGAGTG-
GTGGTTCTGTGCG-3; PAI-1, 5-GACGCCTTCATTTGG-
ACGAA-3 and 5-CGGACCTTTTCCCTTCAAGAGTCCG-
3;CypA, 5-ATGGTCAACCCCACCGTGT-3 and 5-TTCT-
TGCTGTCTTTGGAACTTTGTC-3. Sequences of miRNA-
specific forward primers were designed as follows: miR-130b,
5-CAGTGCAATGATGAAAGGGCAT-3; let-7b, 5-CACA-
TGAGGTAGTAGGTTGTGTG-3; miR-30e*, 5-CTTTCAG-
TCGGATGTTTACAGC-3. CypA served as the internal con-
trol for mRNA, and 18SII RNA (Ambion) served as the internal
control for miRNAs.
3-UTR and Promoter Luciferase Reporters—The mouse
TGF-R1 3-UTR was amplified using primers TGF-R1–3-
UTR-F (5-CAGCTCGAGTGAAACACCGTGGGAACTCT-
G-3) and TGF-R1–3-UTR-R (5-GTCGCGGCCGCATCC-
ATAGTGCACAGAAAGGAC-3). The PCR fragment of TGF-
R1 3-UTR was digested with XhoI and NotI and cloned into
psiCheck-2 (Promega, San Luis Obispo, CA). let-7b and
miR-130b mutant constructs were made via site-directed
mutagenesis using primers let-7bmut-F (5-AGGCTGGTTG-
TTGGATCCCACTGAGAGAAC-3) and let-7bmut-R (5-
GTTCTCTCAGTGGGATCCAACAACCAGCCT-3) and
primers miR-130bmut-F (5-GTCCTTTCTGCTCGAGATG-
GATGCGGCCGC-3) and miR-130bmut-R (5-GCGGCCG-
CATCCATCTCGAGCAGAAAGGAC-3). The promoter
region of mouse 2610318NO2RIK (RIK) was amplified using
primers RIKpromoter-F (5-TCTCGGTACCTGGTCTCCTT-
GAATTCATAGAGA-3) and RIKpromoter-R (5-AGGGCT-
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CGAGTCAGCACCTCGTGGCGCCCT-3). The WT-RIK
promoter (three NF-Y sites) was made by digesting the PCR
fragment of the RIK promoter with KpnI and SacI and cloned
into the pGL4.10 vector (Promega, San Luis Obispo, CA). To
make theNF-Y site-deletion promoter construct (0NF-Y sites),
the PCR fragment was sequentially digested with KpnI and
SmaI and cloned into pGL4.10 vector.
Luciferase Assays—MMC were transfected with plasmids
and/or miRNA mimics or inhibitors using Nucleofector kit
(Lonza, Walkersville, MD) and treated with 10 ng/ml TGF-1.
RIK promoter constructs were co-transfected with pRLTK as a
control for Renilla luciferase (Promega). After 48 h, luciferase
activity was measured using the Luciferase Assay System (Pro-
mega, Madison, WI) and Veritas Microplate luminometer
(Turner Designs, Sunnyvale, CA), in accordance with the man-
ufacturers’ instructions.
Western Blot Analysis—MMC were lysed using 1.5 SDS
buffer. Lysates were then subjected to sonication for 2.5min on
high power (Diagenode-Bioruptor ultrasonicator). Protein
concentrations were measured using Bio-Rad protein assay
reagents. Protein lysates were then fractionated on a 4–15%
gradient gel and transferred to a nitrocellulose membrane.
Membranes were immunoblotted with the following antibod-
ies: TGF-R1 (1:1000 dilution; Santa Cruz Biotechnology, Inc.,
sc-398), NF-YC (1:500 dilution; Santa Cruz Biotechnology,
sc-7715-R), and -actin (1:3000 dilution; Cell Signaling, Bev-
erly, MA). Protein quantitation was performed onGS-800 den-
sitometer using Quantity One software (Bio-Rad).
miRNA Oligonucleotides and siRNAs—All oligonucleotides
representing the miRNA mimics (M), negative control for
mimics (NC-M),miRNA inhibitors (I), and negative control for
the inhibitors (NC-I) were purchased from Thermo Fisher Sci-
entific. Mimics and inhibitors were transfected into MMC at a
final concentration of 20 nM. TGF-R1 and NF-YC siGenome
SMARTpool duplex and non-targeting siRNA control were
purchased from Dharmacon (Lafayette, CO) and transfected
into MMC at a final concentration of 20 nM.
MMCTransfection—MMCwere trypsinized and spun down,
and 1 106 cells were resuspended in 100 l of Basic Nucleo-
fection transfection reagent. miRNA mimic/inhibitor oligonu-
cleotides, mutant constructs, SMARTpool siRNA, or negative
control oligonucleotides were transfected using Amaxa
Nucleofector (Lonza, Basel, Switzerland) according to theman-
ufacturer’s instructions. The transfected cells were serum-de-
pleted the following day for 24 h and then treated with or with-
out 10 ng/ml TGF-1 for the indicated time periods. The cells
were then harvested for luciferase reporter assays and RNA and
protein analysis.
Immunohistochemistry—Formalin-fixed, paraffin-embed-
ded sections were made frommouse kidneys collected 4 weeks
after the onset of diabetes (14). These kidney sections were
mounted onto positively charged slides and incubated with
NF-YC antibody. Periodic acid-Schiff (PAS) staining was per-
formed to determine extracellular matrix accumulation in the
kidney sections. Images of control mice and diabetic mice kid-
ney sections were taken at 40 magnification using an Olym-
pus BX51microscopewith In Studio (PixeraCorp., SantaClara,
CA) software. ImagePro software (Media Cybernetics Inc.,
Rockville, MD) was used to count and quantify staining.
RESULTS
Decreased Expression of miR-130b and let-7b in TGF-1-
treated MMC—We first sought to identify miRNAs that are
differentially regulated under TGF-1-induced (diabetic) con-
ditions in MMC. In examining several candidate miRNAs, we
found a consistent down-regulation of keymembers of the let-7
family, miR-30 family, and miR-130b. We observed a TGF-1-
induced decrease of miR-130b, let-7b, and miR-30e* at 6 and
24 h comparedwith the serum-depleted (SD) control condition
(Fig. 1, A–C). Recent reports have identified TGF-R1 as a tar-
get of let-7c and let-7b in renal cells (30, 32, 33). Interestingly,
computational analysis using Target Scan software identified
TGF-R1 as a potential profibrotic target of not only let-7b but
also the other two miRNAs, miR-130b and miR-30e*. Collagen
type XII 1 (Col12a1) was also identified as a potential target of
miR-30e*with theCol12a1 3-UTRhaving three potentialmiR-
30e* target sites (Fig. 1D). TGF-R1 and Col12a1 mRNA
expression levels were significantly increased at 24 h of TGF-1
treatment, reaffirming the idea that miR-130b and let-7b may
be targeting the TGF-R1 3-UTR, andmiR30e*may be target-
ing the Co12a1 3-UTR in a TGF-1-inducedmanner inMMC
(Fig. 1, E and F). The mRNA expression levels of profibrotic
genes,CTGF (connective tissue growth factor) and PAI-1 (plas-
minogen activator of inhibitor-1) were also evaluated in MMC
as positive controls for TGF-1 treatment because these genes
have been previously shown to be enhanced by TGF-1 in MC
(36–38). As expected, we observed significant increases in
PAI-1 and CTGF mRNA expression, with peak expression
occurring at 6 h after TGF- treatment (Fig. 1, G and H).
TGF-1 Induces TGF-R1Expression viaDown-regulation of
miR-130b and let-7b—It was recently reported that let-7c and
let-7b directly bind and target the TGF-R1 3-UTR in renal
epithelial cells, leading to an attenuation of downstream genes
associated with renal fibrosis (32, 33). let-7 was also shown to
target TGF-R1 in adult human liver cells to regulate human
liver development (30). However, miR-130b has not been
examined previously in DN pathogenesis. We first determined
whether miR-130b and let-7b directly target TGF-R1 in
MMC.We generatedWT as well as mutant luciferase reporter
constructs harboring a single mutation in either the miR-130b
or let-7b binding site within the TGF-R1 3-UTR or a double
mutation where both the miR-130b and let-7b binding sites
were mutated (Fig. 2A). miR-130b sequence alignment on
TGF-R1 3-UTR is at bp 180–186 (Fig. 2B). To determine the
effects of miR-130b on TGF-R1 3-UTR luciferase activity,
MMC were co-transfected with negative control oligonucleo-
tides (NC) or miR-130b mimic or miR-130b inhibitor oligonu-
cleotides. Luciferase activity was significantly reduced in the
presence of exogenous miR-130b mimic (miR-130b-M). Con-
versely,MMCtransfectedwithmiR-130b inhibitor (miR-130-I)
increased the TGF-R1 3-UTR activity (Fig. 2C), verifying that
miR-130b targets TGF-R1 3-UTR.
Next, to verify the effects of let-7b on TGF-R1 3-UTR in
MMC, luciferase reporter assays were performed where WT
or Mut-let-7b (mutation in the let-7b binding site in the
miR-130b and Diabetic Nephropathy
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FIGURE 1. Decreased expression of miR-130b and let-7b in TGF-1-treated MMC. A–C, quantitative PCR analysis of miR-130b, let-7b, and miR-30e*
expression levels in SDMMC treated without or with 10 ng/ml TGF-1 for 6 and 24 h. D, schematic representation of miR-30e* seed sequence alignment and
Col12a1 3-UTR. E–H, TGF-R1, Col12a1, PAI-1, and CTGF mRNA levels were measured in MMC at 6 and 24 h of TGF-1 treatment. TGF-R1 and Col12a1
expression levels were significantly increased at 24 h of TGF-1 treatment, whereas PAI-1 and CTGFmRNA levels were increased at both time periods. Results
for miRNAs were normalized with internal control 18 S. *, **, and ***, p 0.05, p 0.005, and p 0.0005, respectively, versus SD control condition. Expression
of other genes were normalized to CypA internal control. Results shown are mean S.E. (error bars) (n	 3). *, **, and ***, p 0.05, p 0.005, and p 0.0005,
respectively, versus SD control condition.
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TGF-R1 3-UTR) luciferase constructs were co-transfected
with negative control mimic (NC-M) or let-7b mimic
(let7b-M) and treated with or without TGF-1 for 24 h.
WT-TGF-R1 3-UTR co-transfected with NC-M showed a
TGF-1-induced increase in luciferase activity. However,
cells transfected withMut-let-7b showed an increase in basal
activity and still responded to TGF-1 compared with the
WT control condition (Fig. 2D). Similar results were
observed for cells transfected with let-7b-M, where the WT
condition still responded to TGF- 1 and Mut-let-7b
showed an increase in basal activity and also responded to
TGF-1, together demonstrating that loss of the functional
let-7b site (Mut-let-7b-transfected condition) results in an
increase in luciferase activity.
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FIGURE 2. TGF-1 induces TGF-R1 expression via down-regulation of miR-130b and let-7b. A, schematic diagram showing several 3-UTR luciferase
reporter constructs, which includeWT-TGF-R1 3-UTR (with WT intact let-7b andmiR-130b target sites), Mut-miR-130b binding site, Mut-let-7b binding site,
and double mutant (DM; where both miR-130b and let-7b binding sites have been mutated). B, schematic representation of miR-130b seed sequence
alignment to the TGF-R1 3-UTR. C, luciferase reporter assays usingWT-TGF-R1 3-UTR in MMC transfected with miR-130bmimic (M) or miR-130b inhibitor
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NC-M or 130b-M. H, luciferase reporter assays showing increased basal and TGF-1-induced TGF-R1 3-UTR activity in MMC co-transfected with the double
mutant construct and either NC-M, 130b-M, or let-7b-M compared with WT control. Results shown are mean S.E. (error bars) (n	 3). *, **, and ***, p 0.05,
p 0.005, and p 0.0005, respectively, versusWT or NC-M conditions.
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Next, we examined MMC transfected with WT-TGF-R1,
Mut-let-7b, Mut-130b, or double mutant constructs (where
both miR-130b and let-7b binding sites are mutated) and
treated with or without TGF-1 for 24 h (Fig. 2E). Similar to
previous results, Mut-let-7b resulted in an increase in basal
activity but still responded to TGF-1 treatment compared
with WT control. Double mutation on the TGF-R1 3-UTR
resulted in increased basal activity and a TGF-1-induced
increase in TGF-R1 activity. However, no significant differ-
ence was observed with Mut-130b alone compared with WT
control. Because this could be due to ineffectiveness of themiR-
130b mutation, we designed another construct, namely a miR-
130 deletion mutant in which several bases of the miR-130b
target site in the TGF-R1 3-UTR were removed. This miR-
130del construct now showed an increase in basal TGF-R1
activity and an increase in TGF-1 response compared with
WT- TGF-R1 (Fig. 2F).
To determine whether miR-130b and let-7b have additive or
synergistic effects on the TGF-R1 3-UTR, MMC were co-
transfected with WT-TGF-R1 3-UTR and either NC-M, let-
7b-M, 130b-M, or double mimics (D-M; the addition of miR-
130b mimic and let-7b mimic combined) with or without
TGF-1 for 24 h (Fig. 2G). TGF-1-induced TGF-R1 3-UTR
activity was decreased with let-7b-M or miR-130b-M alone.
Interestingly, this decrease was even more pronounced in the
D-M condition (Fig. 2G), suggesting an additive effect between
let-7b andmiR-130b actions on TGF-R1 3-UTR. In addition,
Mut-let-7b constructs were co-transfected with NC-M or
130b-M in the presence or absence of TGF-1 treatment for
24 h. The addition of exogenous miR-130b-M with the Mut-
let-7b construct significantly attenuated basal and TGF-1-in-
duced increase in TGF-R1 3-UTR activity under these con-
ditions (Fig. 2G, last four bars).
Finally, MMC were transfected with WT-TGF-R1 3-UTR
alone or with double mutant constructs along with NC-M,
130b-M, or let-7b-M (Fig. 2H). Similar to previous experi-
ments, whereas we observed a TGF-1-induced increase in
luciferase activity inWT, a further increase in basal activity was
observed with the double mutant construct. The addition of
exogenous mimics, 130b-M or let-7b-M, in combination with
the doublemutant construct had no further additional effect on
the reporter activity relative to NC-M, suggesting, as expected,
that the mimics did not recognize their target sites when
mutated. Taken together, these results demonstrate that miR-
130b and let-7b regulate TGF-R1 3-UTR through their own
target sites in MMC.
In addition, constructs harboring a mutated miR-30e* bind-
ing site on TGF-R1 3-UTR were also tested. Results showed
no significant change in TGF-R1 3-UTR activity with the
miR-30e* binding site mutation (data not shown), suggesting
that TGF-R1 is not a bona fide target of miR-30e*.
miR-130b and let-7b Down-regulate Endogenous TGF-R1
and Col4a1—Next, to determine the effects of miR-130b and
let-7b on endogenous gene expression, we analyzed RNA sam-
ples fromMMC transfected with NC-M, 130b-M, let-7b-M, or
D-M (miR-130b-M and let-7b-M combined).TGF-R1mRNA
expression levels were significantly increased with TGF-1
treatment in the presence of NC-M (Fig. 3A), but this was sig-
nificantly reduced by the addition of exogenous 130b-M or let-
7b-M. This effect was further abrogated in the TGF-1-in-
duced D-M condition, suggesting the additive actions of these
two miRNAs on endogenous target gene expression. Similar to
mRNA levels, TGF-1-induced TGF-R1 protein levels were
also down-regulated with the addition of exogenous mimics
compared with NC-M (Fig. 3B). Notably, there was a further
decrease in the expression levels of TGF-R1 protein in the
D-M condition comparedwith theNC-M condition, again sug-
gesting that miR-130b and let-7b can have additive effects on
decreasing TGF-R1 protein expression. -actin was used as a
loading control (Fig. 3B).
Identifying key players downstream of the miR-130b/let-7b/
TGF-R1 signaling pathway involved in the progression of DN
is imperative to the understanding of this disease. Similar to
TGF-R1, Col4a1 mRNA expression was increased with
TGF-1 treatment in the NC-M sample but significantly
reduced in the presence of exogenous miR-130b and let-7b
mimics, suggesting that Col4a1 expression downstream of
TGF-R1 signaling is also functionally modulated by the
actions of these miRNAs (Fig. 3C).
To further confirm that Col4a1 expression is mediated via
the TGF-R1 pathway, we performed siRNA experiments. The
successful knockdown of TGF-1-induced TGF-R1 expres-
sion led to a decrease in TGF-1-induced Col4a1 mRNA
expression levels compared with the NC (Fig. 3D), indicating
that Col4a1 is a downstream target of the TGF-R1 signaling
pathway and can contribute to fibrosis.
To further test whether inhibition of miR-130b and let-7b
affects TGF-R1 expression, MMC were transfected with
NC-I, 130b-I, let-7b-I, or double inhibitor (D-I; miR-130b
inhibitor and let-7b inhibitor combined) (Fig. 3E). Inhibiting
miR-130b in MMC increased TGF-R1mRNA levels, whereas
let-7b-I alone had no significant effect. No further increase in
TGF-R1 expression was observed even with D-I compared
with miR-130b-I alone, suggesting that miR-130b may be a
more potent regulator of basal TGF-R1 levels than let-7b.
However, this could also be due to lesser efficiency of the let-7b
inhibitor. Taken together, these results suggest that TGF-1
increases profibrotic genes, such asCol4a1, via up-regulation of
TGF-R1mediated at least in part via down-regulation ofmiR-
130b and let-7b, both of which target TGF-R1 (Fig. 3F).
NF-YC Regulates the Promoter of the miR-130b Host Gene—
Because the mechanisms involved in the regulation of miR-
130b expression are unknown,wewere interested in identifying
some of the key players. We examined whether miR-130b
expression depends upon the transcriptional regulation of its
host gene. miR-130b forms a cluster with miR-301b within the
first intron of the 2610318N02RIK (RIK) gene (Fig. 4A). Relative
to cells in the SD condition, MMC treated with TGF-1 for 6
and 24 h showed a significant decrease in RIK mRNA expres-
sion levels. These results suggest that miR-130bmay be co-reg-
ulated with its host gene, RIK (Fig. 4A). Interestingly, further
investigation of the RIK promoter identified the presence of
three potential nuclear transcription factor-Y (NF-Y) sites
located at 200, 240, and 285 bp upstream from the tran-
scription start site (Fig. 4B). To examine whether these NF-Y
sites are important for RIK promoter activity, two luciferase
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reporter constructs were generated (Fig. 4B), a WT-RIK lucif-
erase reporter construct containing all three intact NF-Y sites
and a RIK-Del construct inwhich all threeNF-Y sites have been
removed.MMC cells transfected withWT-RIK in the presence
of TGF-1 showed a significant decrease in RIK promoter
activity, which was further abrogated in the RIK-Del reporter,
suggesting that the absence of NF-Y sites leads to very low pro-
moter activity (Fig. 4B). These results implicate the importance
of the NF-Y sites in regulating the promoter activity of the RIK
gene.
NF-Y consists of three subunits, NF-YA,NF-YB, andNF-YC,
which are highly conserved from Drosophila to humans. NF-Y
complexes have been reported to regulate the transcription of
numerous genes related to the cell cycle, cancer, and various
human diseases (39–45). All three subunits are important for
the formation of NF-Y complexes and bind specifically to
CCAATmotifs within the promoter region of target genes (45,
46). This CCAAT motif is one of the most common cis-acting
elements in the promoter and enhancer region of a large num-
ber of eukaryotic genes (47). Furthermore, this specific motif
has been shown to be enriched in several genes overexpressed
in a variety of cancers, including breast, colon, thyroid, prostate,
and leukemia (48). However, its role in DN is not known. To
further examine the significance of these NF-Y sites on the RIK
promoter, we tested the effect of loss of NF-YC using specific
siRNAs.MMC cells were transfected withWT-RIK or RIK-Del
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reporter constructs and either negative control (NC siRNA) or
NF-YC siRNA (Fig. 4C). The promoter activity ofWT-RIK was
significantly reduced when NF-YC expression was knocked
downwith NF-YC siRNA compared with NC siRNA. Similarly,
the absence of promoter NF-Y sites (RIK-Del construct) signif-
icantly abrogated any promoter activity with or withoutNF-YC
siRNA. These results again implicate the importance of NF-Y
sites in the regulation of RIK promoter activity.
NF-YC Regulates RIK and Other Downstream Components—
Next, wewanted to determinewhether any downstream targets
of RIK and component miRNA, miR-130b, were affected by a
decrease in NF-YC expression. MMC were transfected with
either NC siRNA or NF-YC siRNA and treated with or without
TGF- for 24 h (Fig. 5). NF-YC siRNAdecreasedNF-YCmRNA
expression significantly relative to control NC siRNA (Fig. 5A)
and also reduced the expression of not only RIK but also miR-
130b (Fig. 5, B and C). Conversely, the basal levels of TGF-R1
(the target of miR-130b) was increased by NF-YC siRNA com-
pared with NC siRNA (Fig. 5D). These data reveal a novel feed-
forward regulatory mechanism whereby decreased expression
ofNF-YC leads to a reduction in RIK promoter activity and thus
RIK transcriptional activity, resulting in decreased miR-130b
levels and ultimately increasing TGF-R1 (Fig. 5E).
Expression of miR-130b and Key Parameters of DN in Glom-
eruli of Diabetic Mice—To determine the in vivo relevance of
this signaling cascade, 1TGF-1-2NF-YC-2RIK-2miR-
130b-1TGF-R1, on the progression ofDN,wenext examined
the mRNA expression of these key mediators in the glomeruli
of STZ-injected diabetic mice, 4 weeks after the onset. Similar
to the observations in the in vitro MMC experiments, miR-
130b, let-7b, andRIK showed decreased expression levels in the
glomeruli of diabetic mice compared with their respective con-
trols (Fig. 6, A and B). Conversely, TGF-R1, Col4a1, Col12a1,
PAI-1, and CTGF RNA expression levels were enhanced in the
diabetic mice compared with control mice (Fig. 6, C–E). A sig-
nificant increase in TGF-R1 protein expression levels was also
noted in the diabetic mice (Fig. 6F). Finally, immunohisto-
chemistry staining showed a decrease in glomerular NF-YC
expression in cortical sections of diabetic mice compared with
controlmice (Fig. 6G), reaffirming the notion ofNF-YC as a key
modulator of DN. Quantification of PAS- positive staining in
glomeruli revealed a significant increase in mesangial matrix
accumulation in diabetic mice compared with control mice
(Fig. 6H). These results demonstrate that the signaling cascade
found in in vitro experiments is also relevant in a mouse model
of DN in vivo.
DISCUSSION
TGF-1 is an important regulatory and profibrotic cytokine
that affects the expression of numerous downstream miRNAs
that play a role in the progression of DN (13–21, 33, 49, 50). A
large body of work has been dedicated to identifying key miR-
NAs involved in the renal fibrotic processes because of their
potential to serve as novel biomarkers of therapeutic targets for
DN. In this study, we identified miR-130b as a new player and
also studied the functional role of TGF-1-induced down-reg-
ulation of miR-130b and expression of upstream effectors
related to the pathogenesis of DN. miR-130b was evaluated in
this study because it was found to be significantly down-regu-
lated by TGF-1 in MMC. Several reports have implicated a
role for miR-130b in various cancers (34, 35, 51–54). However,
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the role of miR-130b in DN has not been studied previously. In
the present study, we demonstrate the participation of miR-
130b in a novel signaling cluster and also the functional ability
of TGF-1 to initiate an amplifying cascade involving several
key component players (NF-YC, RIK, miR-130b, and TGF-
R1) that results in the up-regulation of profibrotic factors
associated with the accelerated progression of DN.
Preliminary data from high throughput RNA sequencing3
revealed thatmiR-130b, let-7b, andmiR-30e*were decreased in
a TGF-1-dependent manner in MMC. Further validation of
these data in the current study showed that thesemiRNAswere
down-regulated not only in TGF-1-treated MMC but also in
the glomeruli of diabetic mice (in vivo miR-30e* data not
shown). miRNA mimic and inhibitor experiments confirmed
TGF-R1 to be a bona fide target of miR-130b and let-7b in
MMC. The actions of miR-130b and let-7b on TGF-R1
3-UTR appear to be specific because mutant 3-UTR con-
structs lacking the miR-130b and let-7b binding sites were
unresponsive to mimics. Our data suggest that the down-regu-
lation of miR-130b and let-7b by TGF-1 can cooperatively
enhance, at least in part, the TGF-R1 signaling pathway and
regulate subsequent downstream profibrotic factors, such as
Col4a1. These results also highlight the redundancy among cer-
tain miRNAs, namely miR-130b and let-7b, both with the abil-
ity to target TGF-R1 3-UTR and influence the fibrotic phe-
notype. The data presented in this study suggest that miR-130b
may be a more potent inhibitor of TGF-R1, although more
experiments are needed to confirm this.3 M. Kato and R. Natarajan, unpublished data.
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miR-130b is located within the intron of the non-coding
RNA, 2610318N02RIK (RIK) (UCSCGenomeBrowser), andwe
found that the expressions of both miR-130b and RIK were
similarly down-regulated by TGF-1. Further, miR-130b
expression was dependent upon the transcriptional activity of
the RIK host gene. To date, no known function has been
reported for thisRIK gene. Further analysis of theRIKpromoter
region revealed three functional NF-YC sites capable of regu-
lating the promoter activity of the RIK gene. NF-Y complexes
are composed of three individual subunits (namely NF-YA,
NF-YB, and NF-YC), which bind to promoter CCAAT motifs.
Understanding the mechanism by which TGF-1 down-regu-
lates NF-YC would be beneficial in further elucidating the
importance of NF-YC as a protective factor in DN. Previously,
our group demonstrated that miR-216a is induced by TGF-1
and mediates TGF-1-induced Akt kinase activation and col-
lagen expression in MMC by targeting Ybx1 and Pten (49, 50).
Because Ybx1 also recognizes Y-box (CCAAT) (48), it is possi-
ble that the decrease of RIK and miR-130b is caused by miR-
216a-mediated down-regulation of Ybx1 (49) (Fig. 7). On the
other hand, computational analysis revealed a potential target
site for miR-216a in the NF-YC 3-UTR. However, further
experiments with miR-216a mimics and inhibitors are needed
to fully substantiate NF-YC as a true target of miR-216a.
Interestingly, analysis of the NF-YC genome region also
revealed an miRNA cluster consisting of miR-30e* and miR-
30c-1 within intron 5, suggesting that NF-YC may be the host
gene of miR-30e* and that the expression of miR-30e* may be
dependent on NF-YC expression (Fig. 7). Further experiments
to confirm this and also whether miR-30e* directly targets
Col12a1 3-UTR remain for a future study.
To further examine the in vivo relevance of our in vitro find-
ings, we examined the mRNA expression levels of the key play-
ers within this novel pathway in the glomeruli of diabetic and
control mice. Similar to our in vitro studies, miR-130b, let-7b,
RIK, andNF-YC (immunohistochemistry staining) were down-
regulated in the glomeruli of 4-week STZ-induced diabetic
mice compared with control mice. Conversely, TGF-R1,
Col4a1, PAI-1, and CTGF profibrotic genes were up-regulated
in the diabetic mice.
In summary, the current results demonstrate a novel ampli-
fying cascade where TGF- (diabetic conditions) is able to reg-
ulate the expression of various downstream key components,
including NF-YC and RIK, to down-regulate miR-130b and
thereby increase the expression of pathologic profibrotic genes,
such as TGF-R1 and Col4a1 (Fig. 7). These data also show a
cooperation between miR-130b and let-7b and further add to
our earlier reports demonstrating that severalmiRNAs induced
by TGF-1 can cooperate with each other and create amplify-
ing circuits to fine-tune and augment the progression of DN
(12, 14–16, 49, 50). There are clearly several alternative and
parallel signaling pathways that further enhance the progres-
sion of DN, including Smads and other miRNAs. This collabo-
ration among several key players could explain why our effects
are relatively modest, indicating synergism among these multi-
ple contributing pathways with the ability to cooperatively
accelerate DN.
Notably, here, for the first time, miR-130b has been impli-
cated as a potential protective miRNA in the pathology of renal
fibrosis related to DN. Interestingly, it was previously reported
that miR-130 can modulate adipocyte differentiation by re-
pressing peroxisome proliferator-activated receptor , a key
mediator of adipogenesis, thereby reducing adipogenesis and
limiting the probability of obesity (55). This protective role of
miR-130 in obesity may also translate to its protective role in
DN, whereby increased levels of miR-130 impair the progres-
sion of adipogenesis and insulin resistance and decrease the
potential for developing diabetes and DN. Conversely, the
reduction of miR-130b has the potential to induce not only
FIGURE 6. Expression of miR-130b and key parameters of DN in glomeruli of diabetic mice. A and B, glomeruli were isolated from kidney cortical tissues
from six mice in the control group and ninemice in the STZ-diabetic group. miR-130b, let-7b, and RIKmRNA expression levels were significantly decreased in
glomeruli of STZ-injected diabetic mice (STZ) (4 weeks of diabetes) compared with vehicle-injected (Control) mice. C–E, conversely, TGF-R1, Col4a1, Col12a1,
PAI-1, and CTGF mRNA expression levels were significantly increased in glomeruli of these diabetic mice compared with control non-diabetic mice. Results
shown are mean S.E. (error bars) (n	 3). *, **, and ***, p 0.05, p 0.005, and p 0.0005, respectively, versus control conditions. Results were normalized
to CypA internal control for regular genes and 18 S internal control formiRNAs. F, protein lysates weremade from renal cortical tissues of STZmice and control
mice. TGF-R1 protein expression levels were increased under diabetic conditions compared with control. -Actin was used as a loading control for protein
lysates.G, representativeNF-YC immunostaining images andquantificationusingNF-YCantibody in cortical tissue fromSTZ-injecteddiabeticmiceandcontrol
mice. NF-YC protein expression was significantly reduced in the STZ mice glomeruli compared with control mice. H, representative PAS staining images and
quantification using cortical tissue from STZ-injected diabetic mice and control mice. Significantly increased PAS staining was observed in diabetic mice
compared with control mice. Results shown are mean S.E. * and ***, p 0.05 and p 0.0005 (n	 50 glomeruli counted/condition). Scale bar, 20 m.
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FIGURE 7. Schematicmodel.Under diabetic conditions where TGF-1 levels
are increased,NF-YCexpression is down-regulated (possibly via up-regulated
miR-216a), resulting in reduced binding of NF-YC to the NF-Y sites (CCAAT)
within the RIK promoter. Alternatively, miR-216a can target and down-regu-
late Ybx1, which can result in reduced binding of Ybx1 to Y-box (CCAAT)
within the RIK promoter. Decreased RIK promoter activity leads to reduced
transcriptional activity of theRIKgene, thereby attenuatingmiR-130bexpres-
sion, because miR-130b expression is dependent upon transcriptional activ-
ity of the host gene, RIK. This feed-forward amplifying cascade results in ele-
vated expression of TGF-R1 and subsequently other downstream
profibrotic and ECM genes involved inmediating the progression of diabetic
nephropathy, such as Col4a1, CTGF, and PAI-1. Down-regulation of miR-30e*
might be a consequence of reducedNF-YC, a putative host gene formiR-30e*
that can potentially target Col12a1.
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obesity (or insulin resistance) but also DN. Therefore, reinstat-
ing the levels of miR-130b with oligonucleotide mimics during
high TGF-1 levels (diabetic conditions) would be a potential
translational intervention for reducing renal fibrosis and slow-
ing down the progression of DN. The reno-protective effects of
miR-130b alone or in conjunction with other miRNAs in vivo
could thus be further exploited for the development of better
treatment strategies for DN and other fibrotic disorders.
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